Skip to main content
. Author manuscript; available in PMC: 2008 Jan 1.
Published in final edited form as: Invest Ophthalmol Vis Sci. 2007 Jan;48(1):18–26. doi: 10.1167/iovs.06-0619

FIGURE 4.

FIGURE 4

DHA22:6,n3 treatment depletes cholesterol in caveolae/lipid rafts. hRVE cells were treated with 100 μM palmitic acid16:0 (gray bars) or DHA22:6,n3 (black bars) for 24 hours. Vehicle (20 μM BSA)–treated cells were used as a control (white bars). Water-soluble cholesterol (25 μM cholesterol complexed with 250 μM MCD) was added to DHA22:6,n3-treated cells for 30 minutes (striped bars). Caveolae/lipid raft–enriched domains were purified as described in Experimental Procedures and submitted to total lipid extraction and amino-propyl column fractionation. Neutral lipids were fractionated by normal-phase HPLC analyses. The amount of cholesterol was presented as nmol/μg protein. Data are the mean ± SD of results in three experiments. *P < 0.05 compared with control. #P < 0.05 compared with DHA22:6,n3-treated cells without cholesterol.